Compare Inovio Pharmaceuticals Inc (INO) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Southwest Airlines Co — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Southwest Airlines Co trades at $48.75 (market cap $23.63B). The key difference: Southwest Airlines Co is far larger — about 264.7× Inovio Pharmaceuticals Inc's market cap, and Southwest Airlines Co pays a 1.49% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | LUV | |
|---|---|---|
Market Cap | $89.27M | $23.63B |
Sector | Health | Industrials |
52-Week High | $2.87 | $54.80 |
52-Week Low | $1.05 | $29.06 |
Enterprise Value | $60.28M | $26.70B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Southwest Airlines (LUV) trades at $48.28, up 0.42% today, with a neutral technical signal and mixed earnings history. Recent Q1 2026 EPS missed expectations, but Q4 2025 and Q3 2025 beat. Financials show modest revenue growth to $28.06B in 2025, but net income margin is thin at 2.83%. Analyst consensus is mixed with 42% buy, 47% hold, and 11% sell ratings, and a $52.47 price target implies potential upside. Key news highlights Q2 2026 earnings due July 23, 2026, amid fuel cost volatility and travel demand resilience.
LUV presents a cautious opportunity with upside to the consensus target, supported by operational improvements and sector tailwinds, but risks from fuel price swings, execution challenges, and thin margins warrant careful monitoring. The stock's valuation at a P/E of 32.05 appears elevated relative to earnings growth, requiring strong future performance to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
